Engineered immune cells take on rare blood disorders

NCT ID NCT07603557

Not yet recruiting Disease control Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 4 times

Summary

This phase 2 trial tests a personalized CAR T cell therapy called zolacabtagene autoleucel in 52 adults with chronic immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). The treatment uses the patient's own immune cells, modified to target and destroy faulty B cells that attack blood cells. The study aims to see if this approach can safely improve blood counts and reduce symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zolacabtagene autoleucel (a CAR T cell therapy made from the patient's own immune cells)
What this could lead to: If it works, this could offer a new treatment option for people with chronic ITP or AIHA who have not responded to other therapies, potentially reducing the need for ongoing medication.
What could go wrong: This is an early phase 2 trial with only 52 participants, so results may not apply to everyone. CAR T cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hemolytic anemia autoimmune thrombocytopenic purpura

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE HEMOLYTIC ANEMIA CHRONIC IMMUNE THROMBOCYTOPENIA

Contacts and locations

Locations

Local Institution - 101

Boston, Massachusetts, 02114, United States
Local Institution - 102

Seattle, Washington, 98109, United States
Local Institution - 103

Houston, Texas, 77030-2740, United States
Local Institution - 201

Odense, DK-5000, Denmark
Local Institution - 301

Magdeburg, Saxony-Anhalt, 39120, Germany
Local Institution - 302

Erlangen, 91054, Germany
Local Institution - 401

London, Greater London, W12 OHS, United Kingdom
Local Institution - 402

Sheffield, S10 2SJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.